Research

KU Eye physicians performing cutting-edge, basic, clinical and applied

research in ophthalmology and vision science

Research

 

 

Faculty as Principle Investigator

Dry Eye Assessment and Management (DREAM) Study  (click here for more information and enrollment details!)

Principle Investigator: John Sutphin, MD

Sub-investigator: Miranda Bishara, MD


INTACS Prescription Inserts For Keratoconus--Humanitarian Use Device

Principle Investigator: John Sutphin, MD


Faculty as Sub-Investigator

AGS67E (AGENSYS) - A Phase 1 Study Evaluating Safety, Tolerability and Pharmacokinetics of Escalating Doses of AGS7E given as Monotherapy in Subjects with Refractory or Relapses Lymphoid Malignancies.

Principle Investigator: Ruben Reyes, MD, Hematology/Oncology

Suib-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


ASG-22CE-13-2 (AGENSYS) A Study of Escalating Doses of ASG-22CE as Monotherapy in Subjects with Metastatic Urothelial Cancer

Principle Investigator: Peter Van Veldhuizen, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


ASP2215-CL-0103 (APGD) - A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

Principle Investigator: Tara Lin, MD, Hematology/Oncology

Sub-Investigators: Paul Munden, MD and W. Abraham White, MD


CBYL719XUS06T - PhaseI/II Study of BYL719 and Nab-Paclitaxel in Subjects with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Principle Investigator: Priyanka Sharma, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


CICL670AUS47 - A 2-year, Multi-Center, Phase II, Open-Label, Fixed-Dose, Randomized Comparative Trial of Azacitidine, with or without Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes

Principle Investigator: Abdulraheem Yacoub, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD; and W. Abraham White, MD


GS-US-352-1214 - A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Avaialble Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-Polycythemiai Vera Myelofibrosis or Post-Essential Thrombocytopenic Myelofibrosis who were Treated with Ruxolitinib

Principle Investigator: Abdulraheem Yacoub, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


ISIS304801 - The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia

Principle Investigator: Patrick Moriarty, MD, Clinical Pharmacology

Subj-Investigator: Paul Munden, MD


CD-IA-MEDI-551-1155 - A Double-Masked, Placebo-Controlled Study with Open Label Period to Evaluate MEDI-551 in NMO and NOSD

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Subj-Investigators: Paul Munden, MD; W. Abraham White, MD and Thomas Whittaker, MD


Novartis BA312 - CBAF312X2205 - A Multi-Center, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients with Polymyositis

Principle Investigator: Mazen Dimachkie, MD, Neuromuscular Clinic

Sub-Investigators: Comprehensive Ophthalmologists


S1310 (National Cancer Institute) - Randomized Phaze II Trial of Single Agent MEK Inhibitor Trametinib vs. 5-Fluoroacil or Capecitabine in Refractory Advanced Biliary Cancer

Principle Investigator: Joaquina Baranda, MD, Hematology/Oncology

Sub-Investigators: Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


 

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients with Relapsing Multiple Sclerosis - Not currently enrolling

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: Thomas Whittaker, MD


Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: Thomas Whittaker, MD


A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25 mg FTY720 Administered Orally Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: Thomas Whittaker, MD; Miranda Bishara, MD; Dirck Dekeyser, OD


IMGN853-0401 (First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMGN853 in adults with ovarian cancer and other FOLR1-positive solid tumors (IMGN-0401))

Principle Investigator: KUMC Cancer Center

Sub-Investigators:  Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


A randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with dermatomyositis

Principal Investigator:  Richard Barohn, MD, Neurology, Frontiers: The Heartland Institute for Clinical and Translational Research

Sub-investigators:  Comprehensive Ophthalmologists


A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD, Multiple Sclerosis Clinic

Sub-investigator: OCT exam by technicnians

Last modified: Apr 14, 2015
ID=x8292